Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2016 -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD), a clinical-stage biopharmaceutical company developing novel therapies for cancer, today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will be presenting at the Stifel Healthcare Conference on November 16, 2016, at 8:00 a.m. Eastern Time. A live audio webcast of the presentation will be available in the “Investors” section of Threshold’s website, www.thresholdpharm.com. A replay of the presentation will be archived for 30 days following the conference.
About Threshold Pharmaceuticals
Threshold is a clinical-stage biopharmaceutical company focused on the development of drugs and diagnostic agents targeting the tumor microenvironment of solid tumors and hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit the Company’s website.
Contact: Denise Powell [email protected] 510.703.9491
